Singapore markets close in 3 hours 25 minutes

CSL Limited (CSJ.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
171.75+0.40 (+0.23%)
At close: 09:50PM CET
Full screen
Previous close171.35
Open171.85
Bid171.80 x 20000
Ask172.75 x 20000
Day's range171.75 - 172.65
52-week range136.05 - 194.55
Volume10
Avg. volume18
Market cap83.12B
Beta (5Y monthly)0.29
PE ratio (TTM)36.62
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield2.31 (1.35%)
Ex-dividend date11 Mar 2024
1y target estN/A
  • GlobeNewswire

    Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy

    Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan for the treatment of IgA nephropathy (IgAN) in Europe Positive CHMP opinion is based on pivotal Phase 3 PROTECT Study results European Commission decision is expected in Q2 2024 SAN DIEGO, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) and CSL Vifor today announced that the European Medicines Agency’s (EMA) CHMP has recommended ap

  • PR Newswire Asia

    Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³

    CSL Limited (ASX:CSL; USOTC:CSLLY) today announces a reported net profit after tax of $1.90 billion1 for the 6 months ended 31 December 2023, up 20% on a constant currency basis3. Underlying profit (NPATA) was $2.02 billion1,2, up 13% on a constant currency basis to $2.06 billion1,2,3.

  • PR Newswire

    CSL Announces Top-line Results from the Phase 3 AEGIS-II Trial Evaluating the Efficacy and Safety of CSL112 (apolipoprotein A-I [human])

    Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced top-line results from the Phase 3 AEGIS-II trial evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human]) compared to placebo in reducing the risk of major adverse cardiovascular events (MACE) in patients following an acute myocardial infarction (AMI). The study did not meet its primary efficacy endpoint of MACE reduction at 90 days. As a result, there are no plans for a near-term regulatory filing. There wer